A New Breast Cancer Drug
Results of a trial of Enhertu (trastuzumab deruxtecan) were presented at the 2022 meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine. Enhertu is a specifically engineered HER2-directed antibody drug conjugate which looks for breast cancer cells, binds to the HER2 protein on their surface and then…
Details